Association of genetic polymophisms with pharmacokinetics of levodopa in South indian PD patients
Objective: To evaluate the role of COMT gene variations on the pharmacokinetics (PK) of L-dopa in PD patients. Background: Genetic variations in enzymes (MAO-B, COMT),…Influence of disease severity in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II
Objective: To evaluate the impact of disease severity on the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s disease (PD) patients with motor fluctuations. Background: OPC,…Opicapone and levodopa-carbidopa intestinal gel infusion: a cost saving analysis in the United Kingdom
Objective: To investigate whether the use of Opicapone as an add-on therapy to levodopa-carbidopa intestinal gel (LCIG) infusion in advanced Parkinson’s disease (PD) reduces the…Development of Mucoadhesive Sustained Release Floating Tablets of Silymarin using Natural Polymer for Improved Anti-Parkinson Efficacy
Objective: The objective of the present investigation was to develop Mucoadhesive sustained release floating tablets of Silymarin using natural polymers (Coccinia grandis and Rumex vasicarious)…Clinical Management of Incipient Wearing-off with the 19-Items Wearing off Questionnaire (WOQ-19)
Objective: To evaluate the use of the 19-items Wearing off Questionnaire (WOQ-19) to detect fluctuations in patients with non-advanced Parkinson's disease (PD) and to evaluate…Efficacy and safety of zonisamide in patients with dementia with Lewy bodies with parkinsonism: pooled analysis of phase 2 and 3 trials
Objective: To characterize the efficacy and safety of zonisamide (ZNS) in patients with dementia with Lewy bodies (DLB) with parkinsonism, a pooled analysis of two…GLYCOPAR – A randomized, placebo-controlled, 2-arm parallel-group superiority phase II study of glycopyrrolate for moderate-to-severe sialorrhea in Parkinson’s disease
Objective: To assess the 3-month efficacy and safety of glycopyrrolate for moderate-to-severe sialorrhea in Parkinson’s disease. Background: A systematic review reported that sialorrhea affects approximately…Movement Disorders Patients in Long-Term Care: Protecting Access to Appropriate Treatment
Objective: To better understand the impact of gradual dose reduction (GDR) on patients with movement disorders living in long-term care facilities (LCTFs). Background: More than…Effects of zonisamide on parkinsonism in patients with dementia with Lewy bodies by severity of cognitive dysfunction and BPSD: subgroup analysis of pooled data from two trials
Objective: To characterize the efficacy and safety of zonisamide (ZNS) in patients with dementia with Lewy bodies (DLB) with parkinsonism, we performed subgroup analysis by…Continuous circadian intracerebroventricular administration of anaerobic dopamine: A new therapeutic concept for Parkinson’s disease?
Objective: We aim to overcome these challenges by demonstrating that continuous i.c.v. of Anaerobic-dopamine (A-dopamine,Patent #WO2015173258 A1) close to the striatum is a feasible and…
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 32
- Next Page »